---
title: "Hengrui Medicine drops 8% to record low as H1 adjusted profit falls 13%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296439617.md"
description: "Hengrui Medicine (1276.HK) slid 8% to a record low after H1 adjusted net profit fell 12.7%; buyback plan announced."
datetime: "2026-08-20T05:41:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296439617.md)
  - [en](https://longbridge.com/en/news/296439617.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296439617.md)
generator: "portal-rs"
---

# Hengrui Medicine drops 8% to record low as H1 adjusted profit falls 13%

Hengrui Medicine (1276.HK) fell **8%** during Hong Kong trading on Thursday to HK$50.30, after earlier sliding to a record low of HK$48.80.

The Chinese pharmaceutical group posted first-half revenue of **RMB 15.46 billion**, down **1.9%** year on year, with net profit of **RMB 4.47 billion**, a marginal rise of **0.3%**. Non-recurring items dragged adjusted net profit down **12.7%** to **RMB 3.73 billion**. The company paid no interim dividend.

Innovative drug sales increased **16.4%** to **RMB 8.81 billion**, representing **63%** of total revenue, while R&D spending climbed **19%** to **RMB 4.6 billion**. Hengrui separately announced a **RMB 1 billion-to-2 billion** A-share buyback plan at prices up to **RMB 81.78**, earmarked for employee share-ownership schemes.

Recent pipeline milestones included approval of a fifth indication for its amoxicillin sulfate tablet and a new colorectal-cancer indication for its trastuzumab conjugate. The group also sealed a **US$15.2 billion** strategic partnership with Bristol Myers Squibb, and its affiliate Braveheart Bio completed a Nasdaq listing.

### Related Stocks

- [01276.HK](https://longbridge.com/en/quote/01276.HK.md)

## Related News & Research

- [Chinese Pharma Companies Plan Hong Kong Listings](https://longbridge.com/en/news/297979501.md)
- [Fosun Trims Indian Pharma Stake While Retaining Control](https://longbridge.com/en/news/298132819.md)
- [CLSA: China Biotech Fundamentals Remain Solid; Top Picks BEONE MEDICINES , INNOVENT BIO  and LEADS BIOLABS-B](https://longbridge.com/en/news/297994035.md)
- [Singapore medicine group Eu Yan Sang's founding family sells bungalow for $31M](https://longbridge.com/en/news/298167922.md)
- [00:36 ETRznomics Reports Major Advances in High-Efficiency Circular RNA Production in Nucleic Acids Research](https://longbridge.com/en/news/298166247.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**